おすすめの製品
グレード
certified reference material
品質水準
フォーム
liquid
特徴
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
メーカー／製品名
Cerilliant®
drug control
Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIA (Portugal)
濃度
1.0 mg/mL in methanol
テクニック
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
アプリケーション
forensics and toxicology
フォーマット
single component solution
保管温度
2-8°C
SMILES記法
N3(CCCCC3)C2(CCCCC2)c1ccccc1
InChI
1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2
InChI Key
JTJMJGYZQZDUJJ-UHFFFAOYSA-N
詳細
Phencyclidine, commonly known as PCP, is a recreational drug with hallucinogenic and neurotoxic effects. With street names such as "angel dust" or "wet", PCP comes in either powder or liquid forms. The illicit drug is typically sprayed onto leafy material such as cannabis and then smoked. This certified solution standard is suitable for use as starting material in calibrators and controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing.
Phencyclidine, commonly known as PCP, is a recreational drug with hallucinogenic and neurotoxic effects. With street names such as "angel dust" or "wet", PCP comes in either powder or liquid forms. The illicit drug is typically sprayed onto leafy material such as cannabis and then smoked. This certified solution standard is suitable for use as starting material in calibrators and controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing.
アプリケーション
- A Collaborative Platform for Novel Compound Identification - Characterization of Designer Phencyclidines (PCPs) POXP, PTHP, and P2AP: This research highlights a collaborative platform for the identification and characterization of novel designer PCPs, emphasizing their potential as analytical standards and sigma receptor agonists. The study provides valuable insights for scientists involved in receptor binding studies and the development of dissociative anesthetics for research (Sisco, Urbas, 2023).
- Long-term adaptation of prefrontal circuits in a mouse model of NMDAR hypofunction: Investigating the long-term effects of NMDAR hypofunction in mice, this study uses PCP to elucidate mechanisms of schizophrenia, showcasing its application as a NMDA receptor antagonist in neuropharmacological studies. The findings are crucial for advancing knowledge on neurotransmitter research and mental health disorders (Ponserre et al., 2024).
- 3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an (18)F-FDG PET/CT Case Report: This review and case report discuss the psychiatric implications of 3-Methoxy-Phencyclidine, a derivative of PCP, providing insights into its effects on human cognition and behavior. Such studies are essential for developing high-purity PCP liquids for sigma receptor assays and understanding its role as a non-competitive NMDA antagonist (Pepe et al., 2024).
- Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens: This review explores the dermatological reactions associated with psychedelic drugs, including PCP. It underscores the importance of understanding the biochemical pathways affected by PCP, reinforcing its utility as a research chemical in pharmaceutical applications (Rahman et al., 2024).
- Novel α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) potentiator LT-102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia: This research explores the potential therapeutic uses of AMPAR potentiators, highlighting PCP′s role in enhancing understanding of glutamatergic dysfunction in schizophrenia. It showcases PCP′s utility in developing treatments that modulate neurotransmitter systems, valuable for neuropharmacology research (Qi et al., 2024).
法的情報
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
シグナルワード
Danger
危険有害性情報
危険有害性の分類
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
ターゲットの組織
Eyes,Central nervous system
保管分類コード
3 - Flammable liquids
WGK
WGK 2
引火点(°F)
49.5 °F - closed cup
引火点(℃)
9.7 °C - closed cup
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
消防法
第4類:引火性液体
アルコール類
危険等級II
労働安全衛生法名称等を表示すべき危険物及び有害物
名称等を表示すべき危険物及び有害物
労働安全衛生法名称等を通知すべき危険物及び有害物
名称等を通知すべき危険物及び有害物
Jan Code
P-007-1ML:
P-007-CC:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Ramin Hajikhani et al.
Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 21(3), 307-312 (2012-12-12)
The study attempted to investigate the anti-anxiety activities of Phencyclidine (1-(1-phenylcyclohexyl) piperidine, PCP, I) and some of its derivatives (M, F, L, B, S, P) with the elevated-plus maze (EPM) Test. Phencyclidine and its derivatives (M, F, L, B, S
Daniel C Javitt et al.
Schizophrenia bulletin, 38(5), 958-966 (2012-09-19)
Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors. This article reviews
Jens Köhler et al.
Journal of medicinal chemistry, 55(20), 8953-8957 (2012-09-28)
We synthesized and investigated the NMDA and σ₁ receptor affinity of enantiomerically pure 2-(2-phenyl-1,3-dioxan-4-yl)ethanamines 17-26. The primary amines (R,R)-18-20 with an axially oriented phenyl moiety in position 2 interacted with high enantioselectivity (eudismic ratios 70-130) and high affinity (K(i)((R,R)-19) =
Masakuni Horiguchi et al.
Behavioural brain research, 238, 36-43 (2012-09-29)
Development of dopamine (DA) D(1) receptor agonists is a priority to improve cognitive impairment in schizophrenia (CIS). This study examined the dose-response relationship of the selective D(1) agonist, SKF38393 (0.5-40 mg/kg), to reverse the deficit in novel object recognition (NOR)
Ross Zimnisky et al.
Psychopharmacology, 226(1), 91-100 (2012-10-20)
A major challenge in the pharmacological treatment of psychotic disorders is the effective management of the associated cognitive dysfunctions. Novel concepts emphasize a potential benefit of partial agonists acting upon dopamine D(2)-like receptors in ameliorating these cognitive deficits, and pre-clinical
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）